[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE390438T1 - Stabile, nicht-hygroskopische, kristalline form von n-än-n(4-(piperidin-4-yl)butanoyl)-n- ethylglycyl verbindungen - Google Patents

Stabile, nicht-hygroskopische, kristalline form von n-än-n(4-(piperidin-4-yl)butanoyl)-n- ethylglycyl verbindungen

Info

Publication number
ATE390438T1
ATE390438T1 AT97939488T AT97939488T ATE390438T1 AT E390438 T1 ATE390438 T1 AT E390438T1 AT 97939488 T AT97939488 T AT 97939488T AT 97939488 T AT97939488 T AT 97939488T AT E390438 T1 ATE390438 T1 AT E390438T1
Authority
AT
Austria
Prior art keywords
ethylglycyl
butanoyl
piperidin
hygroscopic
compounds
Prior art date
Application number
AT97939488T
Other languages
English (en)
Inventor
Zofia CHRZAN
James Mencel
David Toledo-Velasquez
Vincent Windisch
Rick WOODWARD
Diane Salazar
Narasimha VEMURI
Anthony GARDETTO
Matthew Powers
Gregory KUBIAK
Robert Liu
Benoit VANASSE
James SHERBINE
Walter Rodriguez
Adam SLEDESKI
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE390438T1 publication Critical patent/ATE390438T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT97939488T 1996-08-21 1997-08-21 Stabile, nicht-hygroskopische, kristalline form von n-än-n(4-(piperidin-4-yl)butanoyl)-n- ethylglycyl verbindungen ATE390438T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2428496P 1996-08-21 1996-08-21

Publications (1)

Publication Number Publication Date
ATE390438T1 true ATE390438T1 (de) 2008-04-15

Family

ID=21819807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939488T ATE390438T1 (de) 1996-08-21 1997-08-21 Stabile, nicht-hygroskopische, kristalline form von n-än-n(4-(piperidin-4-yl)butanoyl)-n- ethylglycyl verbindungen

Country Status (20)

Country Link
US (2) US6153588A (de)
EP (1) EP0923553B1 (de)
JP (1) JP4008499B2 (de)
KR (1) KR20000068229A (de)
CN (2) CN1231659A (de)
AP (1) AP9901462A0 (de)
AT (1) ATE390438T1 (de)
AU (1) AU733591B2 (de)
BG (1) BG63538B1 (de)
BR (1) BR9711340A (de)
CA (1) CA2263647C (de)
DE (1) DE69738601T2 (de)
EA (1) EA001362B1 (de)
IL (1) IL128561A0 (de)
NO (1) NO990721L (de)
OA (1) OA10979A (de)
PL (1) PL331772A1 (de)
SK (1) SK21999A3 (de)
WO (1) WO1998007696A1 (de)
ZA (1) ZA977510B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA977510B (en) * 1996-08-21 1998-05-21 Rhone Poulenc Rorer Pharma Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides.
WO1999019294A1 (en) * 1997-05-14 1999-04-22 Aventis Pharmaceuticals Products Inc. Legal/Patents Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
SK4332000A3 (en) * 1997-10-10 2000-12-11 Rhone Poulenc Rorer Pharma Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
WO2000040601A1 (en) * 1998-12-30 2000-07-13 Aventis Pharmaceuticals Products Inc. Process for preparing a stable non-hygroscopic crystalline n-[n-[n- piperdin- 4-yl)butanoyl)- n.ethylglycyl]- (l)-aspartyl] -ss-cyclohexylalanine amide
US20050238834A1 (en) * 2004-04-21 2005-10-27 Eastman Kodak Company High modulus label with compliant carrier sheet
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US9704557B2 (en) * 2013-09-25 2017-07-11 Qualcomm Incorporated Method and apparatus for storing retention time profile information based on retention time and temperature
CN108697770B (zh) 2015-12-21 2023-08-01 得克萨斯技术大学联合体 用于溶液相gap肽合成的系统和方法
WO2019217116A1 (en) * 2018-05-06 2019-11-14 Gap Peptides Llc Method for solution-phase peptide synthesis
US12024537B2 (en) 2018-05-31 2024-07-02 Sederma Compositions and methods for chemical synthesis
US11827660B2 (en) 2019-02-01 2023-11-28 Sederma Synthesis strategy for gap protecting group

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
US5264420A (en) 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
US5218138A (en) 1992-09-02 1993-06-08 Rhone-Poulenc Rorer Pharmaceuticals Inc. Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5607948A (en) * 1993-06-30 1997-03-04 Sumitomo Pharmaceuticals Co., Ltd. Dipiperidine derivatives
PT812205E (pt) * 1993-10-15 2001-08-30 Rhone Poulenc Rorer Pharma Peptidos e pseudo-peptidos antitromboticos de azacicloalqilalcacoilo
US5780590A (en) * 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
US5707994A (en) * 1993-10-19 1998-01-13 Sumitomo Pharmaceuticals Company, Limited 2,3-diaminopropionic acid derivative
ZA977510B (en) * 1996-08-21 1998-05-21 Rhone Poulenc Rorer Pharma Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides.
SK4332000A3 (en) * 1997-10-10 2000-12-11 Rhone Poulenc Rorer Pharma Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides

Also Published As

Publication number Publication date
PL331772A1 (en) 1999-08-02
US6153588A (en) 2000-11-28
WO1998007696A1 (en) 1998-02-26
AP9901462A0 (en) 1999-03-31
NO990721L (no) 1999-04-20
CN1491942A (zh) 2004-04-28
JP4008499B2 (ja) 2007-11-14
EP0923553A4 (de) 1999-12-08
CN1231659A (zh) 1999-10-13
CA2263647A1 (en) 1998-02-26
BR9711340A (pt) 1999-08-17
ZA977510B (en) 1998-05-21
CA2263647C (en) 2011-02-15
OA10979A (en) 2001-11-01
DE69738601T2 (de) 2009-04-30
AU4156397A (en) 1998-03-06
EP0923553A1 (de) 1999-06-23
IL128561A0 (en) 2000-01-31
US6753409B1 (en) 2004-06-22
AU733591B2 (en) 2001-05-17
DE69738601D1 (de) 2008-05-08
KR20000068229A (ko) 2000-11-25
BG103225A (en) 2000-01-31
NO990721D0 (no) 1999-02-16
EA199900217A1 (ru) 1999-08-26
BG63538B1 (bg) 2002-04-30
JP2000517305A (ja) 2000-12-26
EP0923553B1 (de) 2008-03-26
SK21999A3 (en) 2000-02-14
EA001362B1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
DE69738601D1 (de) Stabile, nicht-hygroskopische, kristalline form von n-än-n(4-(piperidin-4-yl)butanoyl)-n-ethylglycyl verbindungen
ATE228117T1 (de) Kristalline form von 4-(5-methyl-3-phenylisoxazol-4-yl)benzolsulfona id
DE60038481D1 (de) Kristalline form des (r)-2-äää3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinylümethylüsulfinylü-1h-benzimidazols
DE69942555D1 (de) Arylacrylsäureester, verwendbar als Vorstufen von organoleptischen Verbindungen
DK1000028T3 (da) Bicykliske benzamider af 3- eller 4-substituerede 4-(aminomethyl)piperidinderivater
DE69631390D1 (de) Substituierte Benzylaminpiperidin-Verbindungen
NO20003671D0 (no) 4-(2-keto-1-benzimidazolinyl)piperidin-forbindelser som orl1- reseptor agonister
DE69812633D1 (de) Von nitrone- oder nitroso-verbindungen abgeleitete alkoxyaminverbindungen-enthaltende polymerisierbare zusammensetzungen
ATE201872T1 (de) Kristallines hydrochlorid von (r)-(-)-2-(n-(4-(1, 1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl) butyl)-aminomethyl)-chroman
DK199900234U1 (da) Paroxetin-methansulfonat i krystallinsk form, farmaceutisk præparat indeholdende dette og andvendelse af forbindelsen til f
IT8919316A0 (it) Benzoderivati di composti eterociclici contenenti azoto.
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
DE69835817D1 (de) Eutektische verbindung von einkristallinen komponenten
DE59100597D1 (de) Verwendung von N-Alkyl-lactamen als Kristallisationsinhibitoren.
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
ID30516A (id) Senyawa-senyawa (aminoiminometil atau aminometil) benzoheteroaril tersubstitusi
FI943934A0 (fi) Menetelmä fibrinogeenireseptoriantagonisteina käyttökelpoisten 0-(4-(4-piperdinyyli)butyyli)tyrosiinijohdannaisten valmistamiseksi
NO973508L (no) Antipsykotiske 4-(1H-indol-l-yl)-piperidinylderivater
ATE339438T1 (de) Substanziell kristalline form von melagatran
DK1049674T3 (da) Fremgangsmåde til fremstilling af (-) cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl) -piperidin
DK0856513T3 (da) Thalidomidanaloge forbindelser fra gruppen piperidin-2,6-dioner
DK1308454T3 (da) Fremgangsmåde til fremstilling af platinforbindelse
DE59811182D1 (de) Heterocyclische Verbindungen
DK90890A (da) Udvidelsesindretning til opslidsede klemboringer
DK0854146T3 (da) Substitueret 4-(6-fluor-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridin til behandling af CNS forstyrrelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties